ArticleJCI insight2016
Impact of early cART in the gut during acute HIV infection.
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- The Hitchhiker Guide to CD4Frontiers in immunology · 2021Pooled it
- Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.The Journal of clinical investigation · 2022Trial
- TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.EBioMedicine · 2019Trial
- Microbial product translocation and mortality in adults hospitalised with HIV-associated tuberculosis: a prospective observational cohort study.Research square · 2026Article
- The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection.Antimicrobial agents and chemotherapy · 2025Article
- Acute HIV-1 Infection: Paradigm and Singularity.Viruses · 2025Review
- Three-Month cART Initiated During Primary HIV Does Not Correct the Structural, Immune, and Microbial Abnormalities within the Gastrointestinal Tract.Pathogens & immunity · 2025Article
- Nuclear Factor Kappa B p65: A Possible Biomarker for Persistent Inflammation in HIV-1 Infection?Cureus · 2024Review
- Rapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease.medRxiv : the preprint server for health sciences · 2024Article
- In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.Nature medicine · 2023Article
- Prolonged experimental CD4Nature communications · 2023Article
- Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes.iScience · 2023Article
- Cardiovascular Disease and Thrombosis in HIV Infection.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir.Frontiers in immunology · 2023Article
- IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health.JCI insight · 2022Article
- So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.Viruses · 2022Review
- IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells.iScience · 2021Article
- Preferential and persistent impact of acute HIV-1 infection on CD4Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Circulating β-d-Glucan as a Marker of Subclinical Coronary Plaque in Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus.Open forum infectious diseases · 2021Article
- Gut Innate Immunity and HIV Pathogenesis.Current HIV/AIDS reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 3 countries.
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
Alexandra SchuetzDepartment of Retrovirology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. ; US Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
W Gregory AlvordStatistical Consulting, Data Management Services Inc., Frederick, Maryland, USA.
Leslie JohnstonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
Xing-Pei HaoPathology and Histotechnology Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
David R MorcockAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
Rungsun RerknimitrChulalongkorn University, Bangkok, Thailand.
James L K FletcherSEARCH, Bangkok, Thailand. ; Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Suwanna PuttamaswinSEARCH, Bangkok, Thailand. ; Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Nittaya PhanuphakSEARCH, Bangkok, Thailand. ; Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Robin DewarVirus Isolation and Serology Laboratory, Applied and Developmental Research Directorate, Science Applications International Corp., Frederick Inc. National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland, USA.
Joseph M McCuneDivision of Experimental Medicine, Department of Medicine, UCSF, San Francisco, California, USA.
Irini SeretiNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Merlin RobbUS Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Jerome H KimUS Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA. ; SEARCH, Bangkok, Thailand. ; International Vaccine Institute, Seoul, South Korea.
Timothy W SchackerDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Peter HuntPositive Health Program, Department of Medicine, UCSF, San Francisco, California, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
Jintanat AnanworanichUS Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA. ; SEARCH, Bangkok, Thailand.
Jacob D EstesAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
Leidos Biomedical Research Inc. (United States)Thai Red Cross Society · THArmed Forces Research Institute of Medical Science · THChulalongkorn University · THFrederick National Laboratory for Cancer Research · USInternational Vaccine Institute · KRLeidos (United States) · USNational Institute of Allergy and Infectious Diseases · USUniversity of Minnesota · US
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6MVirology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5MImmunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) DiseaseZIAAI001121 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SERETI, IRINI · 2010 to 2025
$27.2MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI028697NIAID NIH HHS U19 AI096109
Abstract
Early after HIV infection there is substantial depletion of CD4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.